Female Contraception Pipeline Review, H1 2018 – ResearchAndMarkets.com

The “Female
Contraception – Pipeline Review, H1 2018” report has been added
to ResearchAndMarkets.com’s offering.

Female Contraception – Pipeline Review, H1 2018 provides comprehensive
information on the therapeutics under development for Female
Contraception (Women’s Health), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Female Contraception (Women’s Health) pipeline guide also reviews of
key players involved in therapeutic development for Female Contraception
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities/Institutes,
the molecules developed by Companies in Filing rejected/Withdrawn, Phase
III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 3,
8 and 4 respectively. Similarly, the Universities portfolio in
Pre-Registration, Phase II and Preclinical stages comprises 1, 1 and 2
molecules, respectively.

Female Contraception (Women’s Health) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/research/2g8mqv/female?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006151/en/